Victor Sandor - 03 Jan 2022 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Role
Director
Signature
/s/ Laurent Chardonnet, Attorney-in-Fact
Issuer symbol
PRLD
Transactions as of
03 Jan 2022
Net transactions value
$0
Form type
4
Filing time
05 Jan 2022, 16:11:42 UTC
Previous filing
14 Oct 2021
Next filing
02 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRLD Director Stock Option (Right to Buy) Award $0 +11,206 $0.000000 11,206 03 Jan 2022 Common Stock 11,206 $13.22 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 1/12 of the total shares monthly beginning on November 13, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.